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We studied the molecular basis of the up to 46-fold in-
creased accumulation of folates and methotrexate (MTX)
in human leukemia CEM-7A cells established by gradual
deprivation of leucovorin (LCV). CEM-7A cells conse-
quently exhibited 10- and 68-fold decreased LCV and folic
acid growth requirements and 23–25-fold hypersensitivity
to MTX and edatrexate. Although CEM-7A cells displayed
a 74–86-fold increase in the reduced folate carrier (RFC)-
mediated influx of LCV and MTX, RFC overexpression per
se cannot induce a prominently increased folate/MTX ac-
cumulation because RFC functions as a nonconcentrative
anion exchanger. We therefore explored the possibility
that folate efflux activity mediated by members of the
multidrug resistance protein (MRP) family was impaired
in CEM-7A cells. Parental CEM cells expressed substan-
tial levels of MRP1, MRP4, poor MRP5 levels, whereas
MRP2, MRP3 and breast cancer resistance protein were
undetectable. In contrast, CEM-7A cells lost 95% of MRP1
levels while retaining parental expression of MRP4 and
MRP5. Consequently, CEM-7A cells displayed a 5-fold de-
crease in the [3H]folic acid efflux rate constant, which was
identical to that obtained with parental CEM cells, when
their folic acid efflux was blocked (78%) with probenecid.
Furthermore, when compared with parental CEM,
CEM-7A cells accumulated 2-fold more calcein fluores-
cence. Treatment of parental cells with the MRP1 efflux
inhibitors MK571 and probenecid resulted in a 60–100%
increase in calcein fluorescence. In contrast, these inhib-
itors failed to alter the calcein fluorescence in CEM-7A
cells, which markedly lost MRP1 expression. Replenish-
ment of LCV in the growth medium of CEM-7A cells re-
sulted in resumption of normal MRP1 expression. These
results establish for the first time that MRP1 is the pri-
mary folate efflux route in CEM leukemia cells and that
the loss of folate efflux activity is an efficient means of
markedly augmenting cellular folate pools. These find-
ings suggest a functional role for MRP1 in the mainte-
nance of cellular folate homeostasis.
Folate cofactors serve as one-carbon donors in the de novo
biosynthesis of purines and thymidylate (1). As such, normal
and neoplastic dividing cells have an absolute folate require-
ment for DNA replication (1). Disruption of folate biosynthesis
with folic acid antagonists (i.e. antifolates) is the pharmacolog-
ical basis for the antitumor activity of methotrexate (MTX)1
and various antifolates (2). Because mammalian cells are de-
void of folate biosynthesis, they rely on folate vitamin uptake
from exogenous sources. Membrane transport of folates and
MTX is mediated by several systems (3, 4): (a) the reduced
folate carrier (RFC) is the major uptake route that functions as
a bi-directional anion exchanger (5, 6) taking up folates
through an antiport exchange mechanism with intracellular
organic phosphates (7); (b) folate receptors mediate the unidi-
rectional uptake of folate cofactors into mammalian cells via an
endocytotic process (8); and (c) an apparently independent
transport system with optimal folate uptake activity at low
pH (9–11).
Apart from RFC, efflux of folates and MTX (12, 13) is medi-
ated by multidrug resistance proteins (MRP) MRP1–4 (14–19),
which belong to the ATP-binding cassette superfamily (20, 21).
Members of the MRP family, currently comprising nine genes
(i.e. MRP1–9), function as ATP-driven efflux transporters of
various natural product anions and acidic charged drug conju-
gates (14, 15). Mammalian cells transfected with MRP1–4 ac-
cumulate decreased levels of MTX and consequently display
resistance to this drug, particularly upon short term drug ex-
posure (16–19). Membrane vesicles isolated from MRP1- and
MRP2-transfected cells exhibit ATP-dependent transport of
MTX (16). Detailed kinetic analysis of folic acid, leucovorin
(LCV; 5-formyl-tetrahydrofolate) and MTX transport into
MRP1- and MRP3-rich membrane vesicles reveals Km values in
the low millimolar range (22). Hence, the free intracellular
level of folates and antifolates including MTX is determined by
the net activities of these influx (i.e. RFC) and efflux (RFC and
MRP) transport pathways.
CEM-7A is a human leukemia CCRF-CEM subline previ-
ously established by gradual deprivation of LCV from the
growth medium (23), resulting in RFC gene amplification (24)
and carrier overexpression (23, 24). Consequently, CEM-7A
cells displayed a marked increase in the influx of MTX and
LCV accompanied by a comparable increase in the steady-state
transmembrane gradient of MTX (23). Surprisingly, however,
there was no increase in the efflux rate constant for MTX (23).
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that upon transfection of RFC cDNA into murine leukemia
cells, there is a marked increase (5–10-fold) in the bi-direc-
tional fluxes (i.e. influx and efflux) of MTX with only a small
increase in the transmembrane gradient. This discrepancy
raised the possibility that the lack of increase in the MTX efflux
rate in CEM-7A cells may be due to a second alteration, such as
a decrease in MRP-mediated folate efflux activity. To explore
this further, studies were undertaken to characterize the bi-
directional fluxes and net transport of folic acid in CEM-7A
cells. Folic acid has a very low affinity for the RFC (26). Thus,
folic acid efflux should be largely mediated by RFC-independ-
ent pathways such as MRPs (14–19). Accordingly, alterations
in folic acid efflux (27) should primarily reflect changes in MRP
expression and efflux activity. We report here that CEM-7A
cells exhibit a high influx and transmembrane gradient for folic
acid, LCV, and MTX and that this is accompanied by a 5-fold
decrease in the folic acid efflux rate constant. This markedly
defective folate export appears to be due to a 95% loss of MRP1
expression, thereby resulting in high transmembrane folate
gradients. These results establish for the first time that MRP1
is the primary folate efflux transporter in CEM leukemia cells
and that the loss of this major folate efflux route is an efficient
means of markedly augmenting cellular folate pools. These
findings suggest a functional role for MRP1 in folate homeo-
stasis in mammalian cells.
MATERIALS AND METHODS
Chemicals—Folic acid, LCV (calcium salt), MTX, probenecid, and
N-hydroxysuccinimide were obtained from Sigma. Trimetrexate (TMQ)
glucoronate was a gift from Warner-Lamber/Parke-Davis (Ann Arbor,
MI), edatrexate was kindly provided by Dr. J. H. Schornagel (Nether-
lands Cancer Institute, Amsterdam, NL), and GW1843U89 ((S)-2[5-
[[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]-1-oxo-2-
isoindolinyl]-glutaric acid) was provided by Dr. G. K. Smith (Glaxo-
Wellcome Research Laboratories). [3,5,7,9-3H]folic acid (25 Ci/mmol),
[3H]MTX (15 Ci/mmol), and [3H]leucovorin (50 Ci/mmol) were obtained
from Moravek Biochemicals (Brea, CA) and purified prior to use as
previously described (28). Calcein AM was from Molecular Probes (Eu-
gene, OR), and MK571 was from Cayman Chemicals (Ann Arbor, MI).
Tissue Culture—Parental CCRF-CEM leukemia cells were grown in
RPMI 1640 medium (Invitrogen) containing 2.3 M folic acid and 10%
fetal calf serum (Invitrogen) supplemented with 2 mM glutamine and
100 g/ml penicillin/streptomycin. CEM-7A cells, originally isolated by
gradual deprivation of LCV from the growth medium (23), were cul-
tured in folic acid-free RPMI 1640 medium (Biological Industries, Beth-
Haemek, Israel) supplemented with 10% dialyzed fetal calf serum (In-
vitrogen), antibiotics, and 0.25 nM leucovorin as the sole folate source.
CEM/MTX (29) and CEM/GW70 cells (30) were originally obtained by
stepwise selection in gradually increasing concentrations of MTX and
GW1843, respectively. CEM/MTX (26) and CEM/GW70 (30) displayed
defective MTX transport because of mutations in the RFC gene. CEM/
MTX and CEM/GW70 were grown in RPMI 1640 medium containing
2.3 M folic acid and 10% fetal calf serum as well as 1 M MTX and 70
nM GW1843, respectively. These cell lines were further selected by
gradual folic acid deprivation, thereby establishing the sublines CEM/
MTX-LF (26) and CEM/GW70-LF (30). These cell lines were cultured in
folate-free RPMI medium containing 10% dialyzed fetal calf serum, 2
mM glutamine, antibiotics as well as 2 and 5 nM folic acid, respectively,
as the sole folate source. The human ovarian carcinoma cell line, 2008,
and its sublines stably transduced with MRP1, 2, 3, and 5 cDNAs were
kindly provided by Prof. P. Borst and Dr. M. Kool (The Netherlands
Cancer Institute, Amsterdam, The Netherlands), whereas HEK293
cells were used as a control for MRP4 overexpression. These cell lines
were cultured in RPMI 1640 medium containing 2.3 M folic acid, 10%
fetal calf serum, 2 mM glutamine, and antibiotics.
Folic Acid and Leucovorin Growth Requirement—Exponentially
growing CEM and CEM-7A cells were washed three times with phos-
phate-buffered saline and transferred to folic acid-free RPMI 1640
medium (Biological Industries) supplemented with 10% dialyzed fetal
calf serum (Invitrogen). Following 4–6 days of growth in folic acid-
deficient medium, cellular growth was arrested. The cells were then
seeded (3  104/well) in medium (0.15 ml) containing increasing con-
centrations of either folic acid or LCV ranging from 1 pM to 3 M in
96-well tissue culture plates. Following 3 days of incubation at 37 °C,
viable cell numbers were determined by hemocytometer count using
Trypan blue exclusion. EC50 is defined as the folic acid concentration
necessary to produce 50% of maximal cell growth.
Antifolate Growth Inhibition—Parental CEM cells and their
CEM-7A subline from the mid-logarithmic phase were seeded in 96-well
plates (3  104/well) in growth medium (0.15 ml/well) containing vari-
ous concentrations of the antifolates MTX or edatrexate. After 3 days of
incubation at 37 °C, cell numbers were determined by hemocytometer
count using Trypan blue exclusion. The 50% inhibitory concentration
(IC50) is defined as the drug concentration at which cell growth is
inhibited by 50% relative to untreated controls.
Transport of Radiolabeled Folates and MTX—Cells (2  107 CEM
and 3  106 CEM-7A cells) at the mid-log phase of growth were washed
three times in an HBS transport buffer containing 20 mM Hepes, 140
mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 mM D-glucose, pH 7.4, with
NaOH (27). The cells were then incubated at 37 °C for 1–30 min in HBS
(1-ml suspensions) containing 2 M [3H]MTX, [3H]LCV, or [3H]folic
acid. TMQ was included (5 M) to block [3H]folic acid and dihydrofolic
acid reduction by dihydrofolate reductase (27). Transport controls con-
tained a 500-fold excess of unlabeled MTX (1 mM). Transport was
stopped by the addition of 10 ml of ice-cold HBS. Then the cell suspen-
sion was centrifuged at 500 g for 5 min at 4 °C, and the cell pellet was
washed twice with 10 ml of ice-cold transport buffer. The final cell pellet
was suspended in 0.2 ml of water, and the radioactivity was determined
on an Ultima Gold (Packard) liquid scintillation spectrometer.
[3H]Folic Acid Efflux—The cells in exponential growth were har-
vested by centrifugation (750  g for 5 min), washed twice with HBS,
and adjusted to a density of 5  106/ml (CEM-7A cells) or 2  107
cells/ml (CEM, CEM/MTX-LF, and CEM/GW70-LF cells) in 10 ml HBS
(pH 7.4 at 37 °C) and then transferred to 50-ml capped tubes and placed
in a shaking 37 °C water bath. Ten min before the addition of [3H]folic
acid, TMQ was added at 5 M and was present during the entire period
of loading and efflux. Following a 20-min loading period, the cells were
centrifuged (750  g for 5 min), the supernatant was aspirated, and the
cell pellet was resuspended in 11 ml of prewarmed (37 °C) HBS and
placed in a shaking water bath at 37 °C. Then 1-ml samples were drawn
and transferred to a centrifuge tube containing 10 ml ice-cold HBS. The
cells were centrifuged, and the cell pellet was processed for radioactiv-
ity. To distinguish between the RFC-mediated and MRP-mediated folic
acid efflux routes, the irreversible RFC inhibitor N-hydroxysuccinimide
ester of MTX (NHS-MTX, 7.5 M) (31) and probenecid (1 mM), which
inhibits MRP1 activity (32), were added to the transport buffer. Because
the influx capacities among the leukemia cell lines differed to a large
extent, CEM/MTX-LF, CEM/GW70-LF, CEM-7A, and parental CEM
cells were loaded to comparable levels with the following [3H]folic acid
concentrations: 2, 2.5, 2.5, and 10 M, respectively. Folic acid efflux
kinetic data were expressed as the log of the ratio of exchangeable
intracellular folate at a given transport time to the initial exchangeable
intracellular level (27).
Western Blot Analysis of MRPs and RFC Expression—To examine
the expression of RFC and the various MRPs in parental CEM cells and
its various sublines (2 107 cells), total cellular proteins were extracted
in a buffer (250 l) containing 50 mM Tris, pH 7.5, 50 mM -mercapto-
ethanol, 0.5% Triton X-100, and the protease inhibitors aprotinin (60
g/ml), leupeptin (5 g/ml), phenylmethylsulfonyl fluoride (10 g/ml),
and EGTA (1 mM). Following 1 h of incubation on ice, the extract was
centrifuged at 15,000  g for 30 min at 4 °C, and the supernatant
containing the fraction of detergent-soluble proteins was collected. The
proteins (10–50 g) were resolved by electrophoresis on 7.5% (for MRP)
or 10% (for RFC) polyacrylamide gels containing SDS and electroblotted
onto a Nytran membrane (Schleicher & Schuell). The blots were blocked
for 1 h at room temperature in Tris-buffered saline (150 mM NaCl, 0.5%
Tween 20, 10 mM Tris, pH 8.0) containing 1% skim milk. The blots were
then reacted with the following anti-human MRP monoclonal antibod-
ies (kindly provided by Prof. R. J. Scheper, VU Medical Center, Am-
sterdam, The Netherlands) at a 1:500 dilution: rat anti-MRP1 (MRP-r1)
and mouse anti-MRP2, anti-MRP3, anti-MRP4 (kindly provided by Dr.
G. D. Kruh), anti-MRP5, anti-BCRP, and anti-Pgp. To determine RFC
expression, the blots were reacted with a polyclonal antiserum (1:700)
prepared in mice against a C-terminal hRFC peptide.2 The blots were
then rinsed in the same buffer for 10 min at room temperature and
reacted with horseradish peroxidase-conjugated goat anti-mouse or an-
ti-rat IgG (1:40,000 dilution; Jackson Immunoresearch Labs, West
Grove, PA) for 1 h at room temperature. Following three 10-min washes
2 I. Ifergan, I. Meller, J. Issakov, and Y. G. Assaraf, submitted for
publication.
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in Tris-buffered saline at room temperature, enhanced chemilumines-
cence detection was assessed according to the manufacturer’s instruc-
tions (Biological Industries). The protein content was determined using
the Bio-Rad protein assay.
Flow Cytometric Analysis of Calcein AM Staining—Exponentially
growing CEM and CEM-7A cells were adjusted to a density of 106/ml
and incubated in growth medium containing 3 nM calcein AM (Molec-
ular Probes, Eugene, OR), a chromophore that in its intracellular ani-
onic form (i.e. calcein), is exported also by MRP1 (33). Following 20 min
of incubation at 37 °C, the cells were harvested by centrifugation,
washed once with phosphate-buffered saline, and analyzed for fluores-
cence intensity per cell by a FACSCalibur flow cytometer (Becton
Dickenson). Excitation was at 488 nm, and emission was at 525 nm. The
autofluorescence intensities of unstained parental CEM and CEM-7A
cells were recorded and subtracted from those of calcein AM-stained cells.
RESULTS
Folate Growth Requirement and Folate/Antifolate Accumula-
tion—Folic acid and LCV growth requirements in parental
CCRF-CEM cells were compared with those of CEM-7A cells
adapted to grow in a medium containing 0.25 nM LCV as the
sole folate source (23). The growth requirements of CEM-7A
cells for folic acid and LCV were markedly decreased when
compared with parental CEM cells. The LCV and folic acid
concentrations necessary to produce 50% maximal growth
(EC50) of CEM-7A cells were 10- and 68-fold lower than those
obtained with parental CEM cells (Table I). Furthermore, rel-
ative to parental CEM cells, CEM 7-A cells were 23- and 25-fold
more sensitive to the dihydrofolate reductase inhibitors MTX
and edatrexate (Table I). Because these results were consistent
with an increased capacity of CEM-7A cells to accumulate
folates and antifolates, the transport of [3H]LCV (Fig. 1A),
[3H]MTX (Fig. 1B), and [3H]Folic acid (Fig. 1C) was determined
in parental CEM and CEM-7A cells. The accumulation of 2 M
tritiated folates and MTX was markedly increased in CEM-7A
cells following 20 min of uptake (Fig. 1); CEM-7A cells accu-
mulated 490  50 pmol LCV, 510  130 pmol of MTX, and 30
pmol of folic acid/107 cells, as compared with 19  4 pmol of
LCV, 16  3 pmol of MTX, and 2 pmol of folic acid/107 cells,
respectively, in parental CEM cells (Table II). Based on the
level of MTX tightly bound to dihydrofolate reductase (deter-
mined by efflux studies), the net MTX and folic acid pools in
CEM-7A cells were 46- and 15-fold higher than in parental
CEM cells, respectively (Table II). Consistently, LCV accumu-
lation in CEM 7A cells was 26-fold higher than that in parental
CEM cells (Table II). This marked accumulation of folates and
MTX was not associated with increased activities of folate-de-
pendent enzymes including dihydrofolate reductase, thymidy-
late synthase, and folylpoly--glutamate synthetase in
CEM-7A cells (23).
[3H]Folic Acid Efflux—The markedly increased levels of fo-
late and MTX accumulation in CEM-7A cells cannot result
from RFC overexpression per se because the latter functions as
an anion exchanger (5, 6) generating very little concentrative
gradients (25). Rather, the high level accumulation of folates
and MTX was suggestive of the loss of some RFC-independent
folate efflux function as previously shown in pyrimethamine-
resistant Chinese hamster ovary cells (27). Hence, folic acid
efflux activity in CEM and CEM-7A cells was determined.
Whereas LCV and MTX are good RFC transport substrates
(Km  1.4 and 5 M, respectively) (23), folic acid is a very poor
transport substrate (Km  175 M) (26). To minimize the RFC-
mediated component of efflux and thereby maximize the ATP-
driven folate efflux route(s), [3H]folic acid rather than [3H]MTX
was used in all efflux studies. [3H]Folic acid efflux was rapid in
parental CEM cells with an average T1⁄2 of 3  1 min (Fig. 2A),
whereas the T1⁄2 in CEM-7A was 5-fold higher (15 4 min) (Fig.
2B). This was consistent with a 5-fold decrease in the folic acid
efflux rate constant in CEM-7A cells relative to parental CEM
cells (Table III). To distinguish between the relative contribu-
tions of RFC and MRPs to the overall efflux of [3H]folic acid, the
N-hydroxysuccinimide ester of MTX (NHS-MTX, 7.5 M), and
probenecid (1 mM), were used as transport inhibitors of RFC
TABLE I
Folate growth requirement and antifolate growth inhibition of
parental CEM and CEM-7A cells
Folate
EC50 (nM)
CEM-7A/CEM
CEM CEM-7A
Fold
Folic acid 54.0  8.0 0.79  0.08 68
Leucovorin 0.2  0.05 0.02  0.01 10
Antifolate
IC50 (nM)
CEM/CEM-7A
CEM CEM-7A
Fold
Methotrexate 1.6  0.5 0.07  0.02 23
Edatrexate 0.5  0.1 0.02  0.01 25
a EC50, is the folate concentration necessary to produce 50% of max-
imal cell growth following a 72-h incubation at 37 °C.
b IC50, antifolate concentration that inhibits cell growth by 50% fol-
lowing a 72-h drug exposure.
c The results depicted are the means  S.D. of 3–6 experiments.
FIG. 1. Time course of folate and MTX uptake in CEM and
CEM-7A cells. Parental CEM cells (squares) and their CEM-7A subline
(circles) were incubated in the presence of 2 M of [3H]LCV (A),
[3H]MTX (B), or [3H]Folic acid (C). For the transport of [3H]folic acid, 5
M TMQ was present in the transport buffer to block folic acid reduction
to tetrahydrofolate (27). Following various times of incubation at 37 °C,
the transport of the radiolabeled folate or MTX was determined as
detailed under “Materials and Methods.”
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(31) and MRP1 (32), respectively. Probenecid induced a 5-fold
fall in the folic acid efflux rate constant in CEM cells (Table
III). Remarkably, the folic acid efflux rate constants obtained
under probenecid inhibition in CEM cells and that of untreated
CEM-7A cells were very low and identical (0.05 min1; see
Table III). Furthermore, incubation of CEM cells with both 7.5
M NHS-MTX and 1 mM probenecid resulted in negligible ad-
ditional inhibition of folic acid efflux beyond the effect achieved
by probenecid alone in both cell lines (Table III). These results
suggested that the major folic acid efflux route present in
parental CEM cells was RFC-independent, inhibitable with
probenecid, and largely lost in CEM-7A cells.
Expression of Various MRPs—Because probenecid has been
shown to inhibit 98% of folic acid efflux mediated by recombi-
nant MRP1 and MRP3 in purified membrane vesicles from Sf9
insect cells (22), the expression of various MRPs and other
members of the ATP-binding cassette superfamily was deter-
mined in CEM and CEM-7A cells. Parental CEM cells ex-
pressed substantial levels of MRP1 (Fig. 3) and MRP4 (Fig. 3B)
and had low levels of MRP5 (Fig. 3B), whereas MRP2, MRP3,
BCRP, and the multidrug resistance transporter Pgp were
undetectable (Fig. 3B). In contrast, CEM-7A cells lost 95% of
parental MRP1 expression (Fig. 3) but had no decrease in the
levels of MRP4 and MRP5 (Fig. 3B). Consistent with the
marked increase in LCV and MTX influx (74–86-fold),
CEM-7A cells had a 30-fold RFC protein overexpression, as
revealed by the reprobing of the MRP Western blot with anti-
hRFC antibodies (Fig. 3A). -Actin expression confirmed that
equal amounts of proteins were being analyzed in the various
gels (Fig. 3B).
Flow Cytometric Analysis of Calcein AM Accumulation—
Calcein AM, a membrane-permeable chromophoric ester of cal-
cein, is rapidly converted by intracellular esterases to its im-
permeable anionic form, calcein. The latter was shown to be a
good efflux substrate of MRP1 (33). Consistent with the loss of
MRP efflux function, CEM-7A cells accumulated 2-fold more
calcein (Fig. 4). Furthermore, inhibition of calcein efflux by the
amphipathic anion, probenecid (1 mM), resulted in a 2-fold
increase in the intracellular calcein fluorescence in CEM cells
with no change in the fluorescence of probenecid-treated
CEM-7A cells (Fig. 4B). Similarly, treatment of CEM cells with
20 M MK571, a specific inhibitor of MRP1 efflux activity (34,
35), resulted in a 60% increase in the calcein fluorescence (Fig.
4B). In contrast, MK571 failed to alter the calcein fluorescence
in CEM-7A cells, which markedly lost MRP1 expression (Fig.
4B). This further indicates that CEM-7A cells were deficient in
an MRP1-mediated anion efflux function.
[3H]Folic Acid Efflux and MRP1 Expression in CEM Sub-
lines Harboring RFC Mutations—To further establish the role
of MRP1 in folic acid efflux, we also studied the sublines CEM/
MTX-LF (26) and CEM/GW70-LF (30) harboring RFC muta-
TABLE III
Folic acid efflux rates in CEM and CEM-7A cells in the absence or
presence of RFC and MRP transport inhibitors
Treatmenta
Folic acid efflux rate constantb
CEM/CEM-7A
CEM CEM-7A
min1 Fold
None (control) 0.25  0.04 0.05  0.01 5
NHS-MTX (7.5 M) 0.1  0.04 0.05  0.01 2
Probenecid (1 mM) 0.05  0.01 0.03  0.01 2
NHS-MTX  probenecid 0.04  0.01 0.01 4
a Exponentially growing cells were washed three times with HBS
loaded with [3H]folic acid to a level of 30–40 pmol/107 cells, and efflux
rate constants were determined in the absence or the presence of RFC
and MRP inhibitors as detailed under “Materials and Methods.”
b The results presented were obtained from 3–5 independent [3H]folic
acid efflux experiments.
TABLE II
Folic acid, leucovorin, and MTX initial uptake rates and accumulation levels in parental CEM and CEM-7A cells
Parameter CEM CEM-7A CEM-7A/CEM
Fold
Folic acid influxa 0.2 5 25
Leucovorin influxa 1.9  0.4 140  20 74
MTX influxa 1.4  0.3 120  30 86
Steady-state folic acid accumulationb 2 30 15
Steady-state leucovorin accumulationb 19  4 490  50 26
Steady-state MTX accumulationb 16  3 510  130 32
Bound MTXc 5 5 1
Net MTX accumulation 11 510 46
a Influx rates are given in pmol/107 cells/min.
b Levels of accumulation of (anti)folate is given in pmol/107 cells.
c Bound MTX levels (pmol/107 cells) were obtained after 60 min of [3H]MTX efflux.
FIG. 2. Time course of [3H]folic acid efflux in parental CEM
cells and their CEM-7A subline. After 30 min of loading (to the same
cellular level) of CEM (A) and CEM-7A cells (B) with 10 and 2.5 M
[3H]folic acid, respectively, in a transport buffer containing 5 M TMQ
at 37 °C, the cells were rapidly centrifuged and resuspended in TMQ-
containing buffer lacking folic acid. Then efflux of [3H]folic acid was
followed for up to 40 min in the absence of inhibitors (solid squares), in
the presence of 1 mM probenecid (open triangles), 7.5 M NHS-MTX
(open squares), or both probenecid and NHS-MTX (solid circles). To
determine the folic acid efflux rate constants, the log value of the
percentage of initial free folic acid obtained at each time point was
plotted as a function of time as previously described (27).
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tions. Following the acquisition of RFC mutations, these sub-
lines were subjected to a gradual deprivation of folic acid,
resulting in growth at 2–5 nM folic acid in the medium. Hence,
the RFC-mediated component of folic acid efflux in these cells
should be minimal, thereby rendering the MRP-mediated ef-
flux of folates more amenable for quantitation. Fig. 5 shows
that whereas parental CEM cells displayed a rapid [3H]folic
acid efflux (T1⁄2  3  1), CEM/MTX-LF and CEM/GW70-LF
cells grown in low folate medium containing only 2 and 5 nM
folic acid, respectively, had substantially increased efflux T1⁄2
values of 10  2 and 6  1, respectively (Table IV). These
translated into 3- and 2-fold decreased folic acid efflux rates in
CEM/MTX-LF (k  0.07 min1) and CEM/GW70-LF cells (k 
0.12 min1), respectively. Because these results were sugges-
tive of decreased MRP1-dependent folate efflux activity, MRP1
expression was determined in CEM/MTX-LF and CEM/
GW70-LF cells (Fig. 6). Relative to parental CEM cells, MRP1
expression was decreased by 3-fold in CEM/MTX-LF cells (Fig.
6A). Remarkably, CEM/MTX-LF cells grown for 1 month in
normal folic acid concentration (i.e. 2.3 M; cells termed CEM/
MTX-LF 3 HF) resumed parental MRP1 expression (Fig. 6A).
Similarly, CEM/GW70-LF cells selected to grow in medium
containing 5 nM folic acid also expressed 3-fold less MRP1
compared with parental CEM and CEM/MTX cells growing in
2.3 M folic acid (Fig. 6B). CEM/GW70-LF cells grown for 1
month in normal folate concentration (i.e. 2.3 M; cells termed
CEM/GW70-LF 3 HF) resumed parental MRP1 expression
(Fig. 6B). Consistently, CEM-7A cells replenished with 5 nM
LCV in the growth medium for 1 month (termed CEM-7A LF3
HF) resumed parental MRP1 expression (Fig. 3A). These re-
sults establish that MRP1 plays a functional role in folate
efflux and suggest a function for MRP1 in cellular folate
homeostasis.
DISCUSSION
In an initial report (23), CCRF-CEM-7A leukemia cells were
shown to have a markedly augmented concentrative transport
of MTX relative to their parental CCRF-CEM cells. This was
associated with RFC gene amplification (24) and carrier over-
expression (23, 24). Because RFC functions as a bi-directional
anion exchanger (5, 6), one would expect that the markedly
augmented influx of MTX in CEM-7A cells should be accompa-
nied with a symmetrical increase in RFC-mediated efflux of
MTX. However, the highly concentrative transport of folates
and MTX in CEM-7A cells was correlated with a marked in-
crease in folate and MTX influx but, surprisingly, without any
change in efflux (23). We therefore undertook the present study
to further explore the molecular basis of this unexpected phe-
FIG. 3. Western blot analysis of RFC and MRP expression in CEM and CEM-7A cells. Exponentially growing CEM and CEM-7A cells
were harvested by centrifugation and lysed in a buffer containing 0.5% Triton X-100 (36). Then detergent-soluble proteins (10–50 g) were resolved
by electrophoresis on 7.5% (for MRP) or 10% (for RFC) polyacrylamide gels containing SDS and electroblotted onto Nytran membranes. The blots
were then reacted with polyclonal antibodies to hRFC (A, lower panel) or monoclonal antibodies to MRP1 (A and B, upper panel), MRP2, MRP3,
MRP4, MRP5, Pgp, and BCRP (B). To confirm the uniformity of protein loading the blots were also reacted with monoclonal antibodies to -actin
(B, lowest panel). A, lane 1, parental CEM cells; lane 2, CEM-7A cells grown in 0.25 nM LCV (LF); lane 3, CEM-7A cells grown in 5 nM LCV for
1 month (LF 3 HF). The molecular masses (kDa) of MRP1 and RFC are given on the right. B, lane 1, parental CEM cells; lane 2, CEM-7A cells
grown at 0.25 nM LCV; lane 3, Various marker cell lines with overexpression of MRP1, MRP2, MRP3, MRP4, MRP5, BCRP, and Pgp, respectively
(starting from the top of the panel). Reprobing with antibodies to -actin was performed to confirm that equal amounts of proteins were being
analyzed (bottom).
FIG. 4. Flow cytometric analysis of calcein accumulation in
CEM and CEM-7A cells. A, exponentially growing CEM (dark line)
and CEM-7A cells (gray line) were incubated for 20 min in growth
medium at 37 °C in the absence (dashed line), or presence of 3 nM
calcein AM (dark and gray lines), washed, and analyzed by flow cytom-
etry for mean fluorescence per cell. B, CEM and CEM-7A cells were
preincubated for 10 min at 37 °C in the absence (dark symbol), or
presence of the calcein efflux inhibitors MK571 (20 M; light gray
shading) or probenecid (1 mM; dark gray shading), after which the cells
were incubated for an additional 20 min in the presence of 3 nM calcein
AMMK571 and probenecid. Then cells were washed and analyzed for
mean fluorescence per cell.
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nomenon. The present data confirm a high level accumulation
of MTX and, in addition, of LCV and folic acid in CEM-7A cells
under conditions in which the reduction and polyglutamylation
of folic acid were suppressed. To explore the role of alterations
in efflux kinetics as the basis for this difference, folic acid was
utilized to exploit its poor affinity for RFC (26), making it a
much better indicator than MTX of changes in MRP-mediated
folate exporter activity.
The following findings are consistent with a marked loss of
folate exporter function in CEM-7A cells: (a) CEM-7A cells had
a 5-fold fall in the folic acid efflux rate constant relative to
parental CEM cells; (b) incubation of parental CEM cells with
probenecid, an organic anion transport inhibitor that also
blocks MRP1 efflux activity (32), blocked 78% of folic acid efflux
and yielded a folic acid efflux rate constant (k  0.05 min1)
that was identical to that obtained with untreated CEM-7A
cells; (c) despite the 86-fold overexpression of RFC-dependent
MTX influx in CEM-7A cells, treatment of CEM-7A and paren-
tal CEM cells with a combination of NHS-MTX (an irreversible
inhibitor of RFC) and probenecid resulted in only a marginal
additional inhibition of folic acid efflux when compared with
probenecid alone; (d) when compared with parental CEM,
CEM-7A cells accumulated 2-fold more calcein, a chromophoric
anionic substrate also exported by MRP1 (33, 35); furthermore,
treatment of parental CEM cells with probenecid and the
MRP1-specific efflux inhibitor, MK571, resulted in resumption
of a calcein fluorescence that was nearly identical to that ob-
tained with CEM-7A cells; and (e) finally, determination of
MRP protein levels revealed that the markedly decreased fo-
late efflux in CEM-7A cells was associated with a dramatic loss
of MRP1 expression in CEM 7A cells. These results establish
that MRP1 is the predominant folate efflux route in human
leukemia CEM cells. However, one cannot rule out the possi-
bility that alternative routes exist that may also contribute, at
least to some extent, to the energy-driven efflux of folates and
antifolates (e.g. MTX) in parental CEM cells. It was recently
shown that the human MRP4 functions not only as an ATP-
driven exporter of nucleotide analogues (37) but also as a high
capacity (Vmax  0.2–2 nmol/mg/min), low affinity (Km  0.2–
0.6 mM) efflux transporter of MTX, folic acid, and LCV (38).
Thus, because MRP4 is equally expressed at substantial levels
in both parental CEM and CEM-7A cells, one cannot exclude
the possibility that under physiological conditions MRP4 may
also contribute to cellular efflux of folates. Furthermore, it is
also possible that some of the most recently discovered MRPs
(but yet insufficiently characterized) including MRP6–9 may
potentially contribute to folate/MTX efflux, at least to some
extent.
Overexpression of murine RFC following cDNA transfection
into MTX transport null mouse leukemia cells resulted in a
marked increase in both MTX influx (10-fold) and efflux (5-fold)
(25). This consequently brought about only a small (2-fold)
increase in the concentrative transport of MTX (25). Hence, the
major impact of the increase in RFC expression was a rapid
cycling of the carrier with a much lesser change in the steady-
state MTX level achieved. Because these cells were obtained by
transfection without folate deprivation or antifolate selective
pressure, there was no apparent requirement or stimulus for
secondary alterations in other transport routes (i.e. such as
decreased MRP1 expression) to sustain growth. On the other
hand, during the establishment of CEM-7A cells, the selection
of parental CEM cells was based upon a gradual LCV depriva-
tion. Because the critical element regulated by the transport
processes is the free cellular folate level achieved, there was an
TABLE IV
Folic acid efflux rates in parental CEM cells and their RFC transport
defective CEM/MTX-LF and CEM/GW-70-LF sublines
Cell line Folic acidefflux (T1⁄2) Parental/variant
min fold
CEM 3  1
CEM/MTX-LF 10  2 3
CEM/GW-70-LF 6  1 2
FIG. 5. Time course of [3H]folic acid efflux in parental CEM
cells and their sublines CEM/MTX-LF and CEM/GW70-LF har-
boring RFC mutations. After 30 min of loading of CEM (solid
squares), CEM/MTX-LF (open squares), and CEM/GW70-LF cells (cir-
cles) with 10, 2, and 2.5 M [3H]folic acid, respectively, in a transport
buffer containing 5 M TMQ at 37 °C, the cells were rapidly centrifuged
and resuspended in TMQ-containing buffer lacking folic acid. Then
efflux of [3H]folic acid was followed for up to 20 min. To determine the
folic acid efflux rate constants, the log value of the percentage of initial
free folic acid obtained at each time point was plotted as a function of
time as previously described (27). FIG. 6. Western blot analysis of MRP1 expression in parental
CEM cells and their CEM/MTX-LF and CEM/GW70-LF sublines
grown under low or high folate concentrations. Triton X-100-
soluble proteins (10–50 g) from parental CEM (A and B), CEM/
MTX-LF (A), and CEM/GW70-LF cells (B) were resolved by electro-
phoresis on 7.5% polyacrylamide gels containing SDS, electroblotted
onto Nytran membranes, and reacted with monoclonal antibodies to
MRP1 as detailed in Fig. 3 legend. LF refers to growth of CEM/MTX-LF
and CEM/GW70-LF under low folate conditions (2 and 5 nM folic acid,
respectively), whereas LF3 HF refers to cellular growth at the regular
medium concentration of folic acid (2.3 M). Reprobing with antibodies
to -actin was performed to confirm that equal amounts of proteins
were being analyzed (bottom panels).
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apparent requirement for a secondary change in efflux with
loss of MRP1 expression aimed at augmenting the intracellular
folate pool to a level sufficient to sustain DNA replication.
In the present paper we provide the first evidence that MRP1
may play a functional role in the maintenance of cellular folate
homeostasis. This is based on the fact that CEM leukemia cells
have, on the one hand, the ability to down-regulate MRP1
expression and folate efflux activity under conditions of folate
deprivation. On the other hand, upon medium repletion with
normal folate levels (2.3 M folic acid), CEM variants (adapted
to grow in nM folic acid or LCV concentrations), resume MRP1
expression. Thus, CEM cells can respond to extracellular folate
status by decreasing MRP1 expression upon folate deprivation
and resume normal MRP1 levels upon repletion of normal
folate concentrations in the growth medium. This mechanism
of adaptation becomes clear when analyzing the cellular folate
pools in CEM-7A, CEM/MTX-LF, and CEM/GW70-LF cells as
compared with their parental CEM cells. Whereas parental
cells contain an average cellular folate pool of 65 pmol/mg
protein (23, 26, 36), CEM-7A (26), CEM/MTX-LF (26), and
CEM/GW70-LF cells (30) possess miniscule folate pools of 1.2,
1.1, and 7.7 pmol/mg protein, respectively. Because these dra-
matically shrunken folate pools represent the lower folate limit
sustaining DNA replication and cell proliferation (36), the cells
must acquire mechanisms to ensure the maintenance of this
minimal cellular folate pools. Indeed, like CEM-7A, CEM/
MTX-LF and CEM/GW70-LF cells had a simultaneous RFC
overexpression (15–30-fold) because of gene amplification (26,
30) and 3-fold decreased MRP1 expression and folate efflux
activity. Furthermore, replenishment of 2.3 M folic acid to
CEM/GW70-LF (30) and CEM-MTX-LF cells (26) resulted in
total folate pools of 303 and 500 pmol/mg protein, respectively.
Consistently, CEM-7A cells accumulated 352 pmol of LCV/mg
of protein upon 20 min of exposure to 2 M LCV (Fig. 1A and
Table II). Thus, replenishment of folates to CEM/GW70-LF,
CEM-7A, and CEM/MTX-LF resulted in 39-, 293-, and 456-fold
expansions in the cellular folate pools when compared with
the cellular folate content obtained with these cells under low
folate growth. These folate pools represented 5–8-fold in-
creases when compared with the total folate content in pa-
rental CEM cells grown under the same conditions. This
dramatic expansion in the cellular folate pools may explain
the resumption of MRP1 expression in these CEM variants
upon folate replenishment. However, the exact molecular
mechanism by which mammalian cells up- or down-regulate
MRP1 expression and folate efflux must await further
characterization.
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